In mouse models of sarcoma, colorectal, breast, and gynecological cancers, TREM2 deletion or blockade with a monoclonal antibody has been shown to reduce tumor growth, enhance antitumor CD8+ T cell responses, including the effectiveness of anti-PD–1 treatment, and modified the TAM landscape61,64. The gene discussed is CD8A; the disease is sarcoma.